Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Journal
Breast cancer research and treatment
Date Issued
2023-06-21
Author(s)
Hsiao, Wen
Dai, Ming-Shen
Chang, Shu-Han
Huang, Shu-Min
Wu, Ko-Wen
Tan, Kien Thiam
Abstract
How to factor both tumor burden and oncogenic genomic mutations as variables to predict the outcome of endocrine-based therapy (ET) in ER-positive/HER2-negative metastatic breast cancer patients (MBC) remains to be explored.
Subjects
Breast cancer; Cell-free tumor DNA; Endocrine receptor; Liquid biopsy
Type
journal article